Please assess the completion status of the following clinical trial:

Trial Title: KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Male or female, ≥18 years~* Pathologically confirmed diagnosis of thymic carcinoma~* Inoperable or metastatic disease~* Had failed at least one regimen containing platinum-based combination chemotherapy for locally advanced unresectable or metastatic disease~* Baseline measurable disease~Exclusion Criteria~* Thymomas, thymolipoma, germ cell tumors, teratomas, seminomas~* Leptomeningeal metastasis or untreated active CNS (central nervous system) metastasis or leptomeningeal metastasis.~* Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks~* Has received other anti-tumor treatment within 4 weeks~* Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment~* Curative radiation within 3 months of the first dose of trial treatment.~* Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thymic carcinoma (Type: EXPERIMENTAL): enrolled subjects will receive KN046 every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).